Microbial antitumor drugs: Natural products of microbial origin as anticancer agents

Current Opinion in Investigational Drugs

Volumn 10, Issue 12, 2009, Pages 1280-1296

  Newman, David J ^a   Cragg, Gordon M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer drug; Microbial genomic; Microbial natural product

Indexed keywords

9,10 DIDEHYDROEPOTHILONE D; ABI 009; ANNAMYCIN; ANTINEOPLASTIC AGENT; BERUBICIN; BMS 753493; DEFOROLIMUS; ENEDIYNE; ENZASTAURIN; EPOTHILONE B; EPOTHILONE DERIVATIVE; EVEROLIMUS; GELDANAMYCIN; ILS 920; IPI 493; IXABEPILONE; NATURAL PRODUCT; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RETASPIMYCIN; SABARUBICIN; SAGOPILONE; SALINOSPORAMIDE A; SGN 35; STAUROSPORINE DERIVATIVE; TAFA 93; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TEMSIROLIMUS; UNCIALAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARCHAEBACTERIUM; BREAST CANCER; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; EUKARYOTE; GENETIC MANIPULATION; GENOMICS; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METABOLITE; MICROORGANISM; NONHUMAN; OVARY CANCER; PROKARYOTE; REVIEW; SARCOMA; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; ARCHAEA; BACTERIA; BIOLOGICAL PRODUCTS; DRUG DESIGN; DRUG DISCOVERY; EUKARYOTA; GENOME; HUMANS; NEOPLASMS;

EID: 71249162039     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. Newman DJ, Cragg GM, Snader KM: Natural products as sources of new drugs over the period 1981-2002. J Nat Prod (2003) 66(7):1022-1037.
2. Newman DJ, Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod (2007) 70(3):461-477.
3. Waksman SA, Woodruff HB: Bacteriostatic and bactericidal substances produced by a soil Actinomyces. Proc Soc Exp Biol Med (1940) 45:609-614.
4. Hackmann C: Experimental investigations on the effects of actinomycin C (HBF 386) in malignancies. Z Krebsforsch (1952) 58(4-5):607-613.
5. Schulte G: Experiences with new cytostatic therapy in blood dyscrasias and carcinomata; differentiation of their effects from the effects of X-rays. Z Krebsforsch (1952) 58(4-5): 500-503.
6. Gniazdowski M, Denny WA, Nelson SM, Czyz M: Transcription factors as targets for DNA-interacting drugs. Curr Med Chem (2003) 10(11):909-924.
7. Arcamone FM: Anthracyclines. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DGI, Newman DJ (Eds), Taylor and Francis, Boca Raton, FL, USA (2005):299-320.
8. Tao Z-F, Konishi K, Keith G, Hecht SM: An efficient mammalian transfer RNA target for bleomycin. J Am Chem Soc (2006) 128(46):14806-14807.
9. Akiyama Y, Ma Q, Edgar E, Laikhter A, Hecht SM: Identification of strong DNA binding motifs for bleomycin. J Am Chem Soc (2008) 130(30):9650-9651.
10. Hamann PR, Upeslacis J, Borders DB: Enediynes. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DGI, Newman DJ (Eds), Taylor and Francis, Boca Raton, FL, USA (2005):451-474.
11. Van Lanen SG, Shen B: Biosynthesis of enediyne antitumor antibiotics. Curr Top Med Chem (2008) 8(6):448-459.
12. Scott AM, Herbertson RA, Lee FT, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, Tebutt NC: Phase I biodistribution study of Ley targeting immunoconjugate in advanced epithelial cancers. J Clin Oncol (2008) 26(15S): Abs 3025.
13. DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK: Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res (2006) 12(1):242-249.
14. Castillo J, Winer E, Quesenberry P: Newer monoclonal antibodies for hematological malignancies. Exp Hematol (2008) 36(7): 755-768.
15. Nicolaou KC, Chen JS, Zhang H, Montero A: Asymmetric synthesis and biological properties of uncialamycin and 26-epi-uncialamycin. Angew Chem Int Ed (2008) 47(1):185-189.
16. Sehgal SN, Baker H, Vézina C: Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation, and characterization. J Antibiot (1975) 28(10):727-732.
17. Vézina C, Kudelski A, Sehgal SN: Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (1975) 28(10):721-726.
18. Baker H, Sidorowicz A, Sehgal SN, Vezina C: Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (1978) 31(6):539-545.
19. Eng CP, Sehgal SN, Vézina C: Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (1984) 37(10):1231-1237.
20. Isotechnika Inc: FDA grants permission to Isotechnika for TAFA-93 clinical trial. Press Release (2004): July 97.
21. Koehn FE: Therapeutic potential of natural product signal transduction agents. Curr Opin Biotechnol (2006) 17(6):631-637.
22. Newman DJ: Natural products as leads to potential drugs: An old process or the new hope for drug discovery? J Med Chem (2008) 51(9):2589-2599.
23. Ruan B, Pong K, Jow F, Bowlby M, Crozier RA, Liu D, Liang S, Chen Y, Mercado ML, Feng X, Bennett F et al: Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci USA (2008) 105(1):33-38.
24. Chambraud B, Belabes H, Fontaine-Lenoir V, Fellous A, Baulieu EE: The immunophilin FKBP52 specifically binds to tubulin and prevents microtubule formation. FASEB J (2007) 21(11):2787-2797.
25. Hoefle G, Reichenbach H: Epothilone, a myxobacterial metabolite with promising antitumor activity. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DGI, Newman DJ (Eds), Taylor and Francis, Boca Raton, FL, USA (2005): 413-450.
26. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res (1995) 55(11):2325-2333.
27. Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB: Total synthesis and antitumor activity of ZK-EPO: The first fully synthetic epothilone in clinical development. Angew Chem Int Ed (2006) 45(47):7942-7948.
28. Altmann KH, Gertsch J: Anticancer drugs from nature - Natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep (2007) 24(2):327-357.
29. Altmann KH, Pfeiffer B, Arseniyadis S, Pratt BA, Nicolaou KC: The chemistry and biology of epothilones - The wheel keeps turning. Chem Med Chem (2007) 2(4):396-423.
30. Feyen F, Cachoux F, Gertsch J, Wartmann M, Altmann KH: Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc Chem Res (2008) 41(1):21-31.
31. Altmann KH, Memmert K: Epothilones as lead structures for new anticancer drugs - Pharmacology, fermentation, and structure-activity-relationships. In: Progress In Drug Research. Petersen F, Amstutz R (Eds), Springer, Berlin, Germany (2008) 66:275-334.
32. Hearn BR, Zhang D, Li Y, Myles DC: C-15 thiazol-4-yl analogues of (E)-9,10-didehydroepothilone D: Synthesis and cytotoxicity. Org Lett (2006) 8(14):3057-3059.
33. Cho YS, Wu K-D, Moore MAS, Chou T-C, Danishefsky SJ: Secondgeneration epothilones: Discovery of fludelone and its extraordinary antitumor properties. Drugs Future (2005) 30(7):737-745.
34. Chou T-C, Zhang X-G, Dong H, Zhong Z, Feng L, Li Y, Sherrill M, Timmermanns P, Johnson RG Jr, Danishefsky SJ: Iso-oxazole-fludelone (KOS-1803) as a potent and efficacious microtubule-stabilization epothilone against xenograft tumors. Proc Am Assoc Cancer Res (2008):Abs 1402.
35. Chou TC, Zhang X, Zhong ZY, Li Y, Feng L, Eng S, Myles DR, Johnson R Jr, Wu N, Yin YI, Wilson RM et al: Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones. Proc Natl Acad Sci USA (2008) 105(35):13157-13162.
36. Leamon CP: Folate-targeted drug strategies for the treatment of cancer. Curr Opin Invest Drugs (2008) 9(12):1277-1286.
37. Frank B, Müller R: Neue wirkstoffe aus myxobakterien: Wie mikroorganismen den krebs bekämpfen helfen. Pharmazeutische Zeitung (2007) 152(50):64-69.
38. Schneiker S, Perlova O, Kaiser O, Gerth K, Alici A, Altmeyer MO, Bartels D, Bekel T, Beyer S, Bode E, Bode HB et al: Complete genome sequence of the myxobacterium Sorangium cellulosum. Nat Biotechnol (2007) 25(11):1281-1289.
39. Wenzel SC, Müller R: Myxobacterial natural product assembly lines: Fascinating examples of curious biochemistry. Nat Prod Rep (2007) 24(6):1211-1224.
40. DeBoer C, Meulman PA, Wnuk RJ, Peterson DH: Geldanamycin, a new antibiotic. J Antibiot (1970) 23(9):442-447.
41. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA (1994) 91(18):8324-8328.
42. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP: Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell (1997) 89(2):239-250.
43. Snader KM: Benzoquinone ansamycins. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DGI, Newman DJ (Eds), Taylor and Francis, Boca Raton, FL, USA (2005):339-356.
44. Kingston DG, Newman DJ: The search for novel drug leads for predominately antitumor therapies by utilizing mother nature's pharmacophoric libraries. Curr Opin Drug Discovery Dev (2005) 8(2):207-227.
45. Patterson J, Palombella VJ, Fritz C, Normant E: IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol (2008) 61(6):923-932.
46. Johnston JS, Phelps MA, Blum KA, Blum W, Grever MR, Farley KL, Dalton JT: Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17- demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma. J Chromatogr B (2008) 871(1):15-21.
47. Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchiya H, Takahashi Y, Masuma R: A new alkaloid AM-2282 of Streptomyces origin. Fermentation, isolation and preliminary characterization. J Antibiot (1977) 30(4):275-282.
48. Prudhomme M: Staurosporines and structurally related indolocarbazoles as antitumor agents. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DGI, Newman DJ (Eds), Taylor and Francis, Boca Raton, FL, USA (2005):499-517.
49. Borthakur G, Alvarado Y, Ravandi-Kashandi F, Cortes J, Estrov Z, Faderi S, Ivy P, Bueso-Ramos C, Bekele BN, Giles F: Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer (2008) 113(2):360-366.
50. Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer E: Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules. Invest New Drugs (2007) 25(2):161-164.
51. Eli Lilly & Co: Data monitoring committee recommends closing enrollment in recurrent glioblastoma study. Press release (2006): December 21.
52. Chen Y-B, LaCasce AS: Enzastaurin. Expert Opin Invest Drugs (2008) 17(6):939-944.
53. Jane EP, Pollack IF: The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells. Cancer Lett (2008) 268(1):46-55.
54. Johnstone RW: Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov (2002) 1(4): 287-299.
55. De Ruijter AJ, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg AB: Histone deacetylases: Characterization of the classical HDAC family. Biochem J (2003) 370(Pt 3):737-749.
56. Kristelett R, Stimson L, Workman P, Aherne W: Histone modification enzymes: Novel targets for cancer drugs. Expert Opin Emerg Drugs (2004) 9(1):135-154.
57. Dokmanovic M, Clarke C, Marks PA: Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res (2007) 5(10):981-989. (Pubitemid 350080267)
58. Paris M, Porcelloni M, Binaschi M, Fattori D: Histone deacetylase inhibitors: From bench to clinic. J Med Chem (2008) 51(6):1505-1529.
59. Michan S, Sinclair D: Sirtuin in mammals: Insights into their biological function. Biochem J (2007) 404(1):1-13.
60. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S: Histone deacetylase as a new target of cancer chemotherapy. Cancer Chemother Pharmacol (2001) 48(Suppl):S20-S26.
61. Remiszewski SW: Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr Opin Drug Discovery Dev (2002) 5(4):487-499.
62. Yoshida M, Matsuyama A, Komatsu Y, Nishino N: From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem (2003) 10(22):2351-2358.
63. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (1994) 47(3):301-310. (Pubitemid 24106520)
64. Furumai R, Matsuyama A, Kobashi N, Lee K-H, Nishiyama M, Nakajima H, Tanaka A, Komatsu Y, Nishino N, Yoshida M, Horinouchi S: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res (2002) 62(17):4916-4921.
65. Gloucester Pharmaceuticals Inc: Gloucester Pharmaceuticals acquires worldwide development and commercialization rights to novel anti-cancer compound from Fujisawa. Press Release (2004): April 15.
66. Gloucester Pharmaceuticals Inc: FDA approves Gloucester Pharmaceuticals' Istodax for patients with cutaneous T-cell lymphoma. Press Release (2009): November 09.
67. Yuhta M, Nobuaki S, Noriaki I: Histone deacetylase inhibitors from microorganisms: The Astellas experience. In: Progress in Drug Research. Petersen F, Amstutz R (Eds), Birkhauser Verlag, Basel, Switzerland (2008) 66:337-359.
68. Wen S, Packham G, Ganesan A: Macrolactamization versus macrolactonization: Total synthesis of FK228, the depsipeptide histone deacetylase inhibitor. J Org Chem (2008) 73(23):9353-9361.
69. Di Maro S, Pong R-C, Hsieh J-T, Ahn J-M: Efficient solid-phase synthesis of FK228 analogues as potent antitumoral agents. J Med Chem (2008) 51(21):6639-6641.
70. Meragelman TL, Cardellina II JH, Britt JR, Shipley SM, McCloud TG, Newman DJ, Shoemaker RH: Bacterial histone deacetylase inhibitor isolated from several Rubiaceae species. A mutualistic association? Annual Oxford International Conference on the Science of Botanicals and American Society of Pharmacognosy Fourth Interim Meeting, Oxford, MS, USA (2008) 7:Abs 40.
71. Nguyen T, Ishida K, Jenke-Kodama H, Dittmann E, Gurgui C, Hochmuth T, Taudien S, Platzer M, Hertweck C, Piel J: Exploiting the mosaic structure of trans-acyltransferase polyketide synthases for natural product discovery and pathway dissection. Nat Biotechnol (2008) 26(2):225-233.
72. Taylor MW, Hill RT, Piel J, Thacker RW, Hentschel U: Soaking it up: The complex lives of marine sponges and their microbial associates. ISME J (2007) 1(3):187-190.
73. Williams PG: Panning for chemical gold: Marine bacteria as a source of new therapeutics. Trends Biotechnol (2009) 27(1):45-52.
74. Newman DJ: The bryostatins. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DGI, Newman DJ (Eds), Taylor and Francis, Boca Raton, FL, USA (2005):137-150.
75. Flahive E, Srirangam J: The dolastatins: Novel antitumor agents from Dolabella auricularia. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DGI, Newman DJ (Eds), Taylor and Francis, Boca Raton, FL, USA (2005):191-214.
76. Lopanik NB, Shields JA, Buchholz TJ, Rath CM, Hothersall J, Haygood MG, Håkansson K, Thomas CM, Sherman DH: In vivo and in vitro trans-acylation by BryP, the putative bryostatin pathway acyltransferase derived from an uncultured marine symbiont. Chem Biol (2008) 15(11):1175-1186.
77. Charette A: Short cuts to complexity. Nature (2008) 456(7221): 451-453.
78. Trost BM, Dong G: Total synthesis of bryostatin 16 using atom-economical and chemoselective approaches. Nature (2008) 456(7221):485-488.
79. Wender PA, DeChristopher BA, Schrier AJ: Efficient synthetic access to a new family of highly potent bryostatin analogues via a Prins-driven macrocyclization strategy. J Am Chem Soc (2008) 130(21):6658-6659.
80. Wender PA, Verma VA, Paxton TJ, Pillow TH: Function-oriented synthesis, step economy, and drug design. Acc Chem Res (2008) 41(1):40-49.
81. Keck GE, Kraft MB, Truong AP, Li W, Sanchez CC, Kedei N, Lewin NE, Blumberg PM: Convergent assembly of highly potent analogues of bryostatin 1 via pyran annulation: Bryostatin look-alikes that mimic phorbol ester function. J Am Chem Soc (2008) 130(21):6660-6661.
82. Sun MK, Hongpaisan J, Nelson TJ, Alkon DL: Poststroke neuronal rescue and synaptogenesis mediated in vivo by protein kinase C in adult brains. Proc Nat Acad Sci USA (2008) 105(36):13620-13625.
83. Wang D, Darwish DS, Schreurs BG, Alkon DL: Analysis of longterm cognitive-enhancing effects of bryostatin-1 on the rabbit (Oryctolagus cuniculus) nictitating membrane response. Behav Pharmacol (2008) 19(3):245-256.
84. Luesch H, Moore RE, Paul VJ, Mooberry SL, Corbett TH: Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod (2001) 64(7):907-910.
85. Ramaswamy AV, Flatt PM, Edwards DJ, Simmons TL, Han B, Gerwick WH: The secondary metabolites and biosynthetic gene clusters of marine cyanobacteria. Applications in biotechnology. In: Frontiers in Marine Biotechnology. Proksch P, Mueller WEG (Eds), Horizon Bioscience, Norwich, UK (2006): 175-224.
86. Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G et al: Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res (2006) 66(4):2328-2337.
87. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD et al: Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptidelinked anti-CD30-auristatin conjugates. J Biol Chem (2006) 281(15):10540-10547.
88. Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber H-P: Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol (2008) 142(1): 69-73.
89. Pollack VA, Alvarez E, Tse KF, Torgov MY, Xie S, Shenoy SG, MacDougall JR, Arrol S, Zhong H, Gerwien RW, Hahne WF et al: Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011- vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol (2007) 60(3):423-435.
90. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ, Olson WC: Potent antitumor activity of an auristatinconjugated, fully human monoclonal antibody to prostatespecific membrane antigen. Clin Cancer Res (2006) 12(8):2591-2596.
91. Rinehart K, Holt TG, Fregeau NL, Stroh JG, Kiefer PA, Sun F, Li LH, Martin DG: Ecteinascidins 729, 743, 745, 759A, 759B and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem (1990) 55(15):4512-4515.
92. Wright AE, Forleo DA, Gunawardana GP, Gunasekera SP, Koehn FE, McConnell OJ: Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata. J Org Chem (1990) 55(15):4508-4512.
93. Henriquez R, Faircloth G, Cuevas C: Ecteinascidin 743 (ET-743; YondelisTM), aplidin, and kahalalide F. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DGI, Newman DJ (Eds), Taylor and Francis, Boca Raton, FL, USA (2005):215-240.
94. Velasco A, Acebo P, Gomez A, Schleissner C, Rodríguez P, Aparicio T, Conde S, Muñoz R, de la Calle F, Garcia JL, Sánchez-Puelles JM: Molecular characterization of the safracin biosynthetic pathway from Pseudomonas fluorescens A2-2: Designing new cytoxic compounds. Mol Microbiol (2005) 56(1):144-154.
95. Moss C, Green DH, Perez B, Velasco A, Henriquez R, McKenzie JD: Intracellular bacteria associated with the ascidian Ecteinascidia turbinata: Phylogenic and in situ hybridization analysis. Marine Biol (2003) 143(1):99-110.
96. Perez-Matos AE, Rosado W, Govind NS: Bacterial diversity associated with the Caribbean tunicate Ecteinascidia turbinata. Antonie van Leeuwenhoek (2007) 92(2):155-164.
97. Hamann MT, Otto CS, Scheuer PJ, Dunbar DC: Kahalalides: Bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp. J Org Chem (1996) 61(19):6594-6600.
98. López-Macià A, Jiménez JC, Royo M, Giralt E, Albericio F: Synthesis and structure determination of kahalalide F (1,2). J Am Chem Soc (2001) 123(46):11398-11401.
99. Zeltia: On this day, 19 December 2000, Pharma Mar SA has commenced phase I clinical trials for kahalalide F (KF). Press release (2000): December 19.
100. PharmaMar SA: PharmaMar reports new data on kahalalide-F and aplidin at ESMO congress. Press Release (2006): September 29.
101. Shilabin AG, Kasanah N, Wedge DE, Hamann MT: Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: Semisynthetic modifications and antifungal lead-exploration studies. J Med Chem (2007) 50(18):4340-4350.
102. Jiménez JC, López-Macià A, Gracia C, Varón S, Carrascal M, Caba JM, Royo M, Francesch AM, Cuevas C, Giralt E, Albericio F: Structureactivity relationship of kahalalide F synthetic analogues. J Med Chem (2008) 51(16):4920-4931.
103. Piggott AM, Karuso P: Rapid identification of a protein binding partner for the marine natural product kahalalide F by using reverse chemical proteomics. ChemBioChem (2008) 9(4): 524-530.
104. West LM, Northcote PT: Peloruside A: A potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem (2000) 65(2):445-449.
105. Hood KA, West LM, Rouwé B, Northcote PT, Berridge MV, Wakefield SJ, Miller JH: Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res (2002) 62(12):3356-3360.
106. Gaitanos TN, Buey RM, Diaz JF, Northcote PT, Teesdale-Spittle P, Andreu JM, Miller JH: Peloruside A does not bind to the taxoid site on ?-tubulin and retains its activity in multidrug-resistant cell lines. Cancer Res (2004) 64(15):5063-5067.
107. Huzil JT, Chik JK, Slysz GW, Freedman H, Tuszynski J, Taylor RE, Sackett DL, Schriemer DC: A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol (2008) 378(5):1016-1030.
108. Jiménez-Barbero J, Canales A, Northcote PT, Buey RM, Andreu JM, Díaz JF: NMR determination of the bioactive conformation of peloruside A bound to microtubules. J Am Chem Soc (2006) 128(27):8757-8765.
109. Page M, West L, Northcote P, Battershill C, Kelly M: Spatial and temporal variability of cytotoxic metabolites in populations of the New Zealand sponge Mycale hentscheli. J Chem Ecol (2005) 31(5):1161-1174.
110. Page MJ, Northcote PT, Webb VL, Mackey S, Handley SJ: Aquaculture trials for the production of biologically active metabolites in the New Zealand sponge Mycale hentscheli (Demospongiae: Poecilosclerida). Aquaculture (2005) 250(1-2):256-269.
111. Liao X, Wu Y, De Brabander JK: Total synthesis and absolute configuration of the novel microtubule-stabilizing agent peloruside A. Angew Chem Int Ed (2003) 42(14):1648-1652.
112. Jin M, Taylor RE: Total synthesis of (+)- peloruside A. Org Lett (2005) 7(7):1303-1305.
113. Ghosh AK, Xu X, Kim JH, Xu CX: Enantioselective total synthesis of peloruside A: A potent microtubule stabilizer. Org Lett (2008) 10(5):1001-1004.
114. Williams DR, Nag PP, Zorn N: Strategies for the synthesis of the novel antitumor agent peloruside A. Curr Opin Drug Discovery Dev (2008) 11(2):251-271.
115. Newman DJ, Hill RT: New drugs from marine microbes: The tide is turning. J Ind Microbiol Biotechnol (2006) 33(7):539-544.
116. Jensen PR, Fenical W: New natural-product diversity from marine actinomycetes. In: Natural Products. Zhang L, Demain AL (Eds), Humana Press Ltd, Towata, NJ, USA (2005):315-328.
117. Jensen PR, Mincer TJ, Williams PG, Fenical W: Marine actinomycete diversity and natural product discovery. Antonie van Leeuwenhoek (2005) 87(1):43-48.
118. Fenical W, Jensen PR: Developing a new resource for drug discovery: Marine actinomycete bacteria. Nat Chem Biol (2006) 2(12):666-673.
119. Gontang EA, Fenical W, Jensen PR: Phylogenetic diversity of gram-positive bacteria cultured from marine sediments. Appl Environ Microbiol (2007) 73(10):3272-3282.
120. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W: Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora. Angew Chem Int Ed (2003) 42(3):355-357.
121. Reddy LR, Saravanan P, Corey EJ: A simple stereocontrolled synthesis of salinosporamide A. J Am Chem Soc (2004) 126(20):6230-6231.
122. Endo A, Danishefsky SJ: Total synthesis of salinosporamide A. J Am Chem Soc (2005) 127(23):8298-8299.
123. Macherla VR, Mitchell SS, Manam RR, Reed KA, Chao TH, Nicholson B, Deyanat-Yazdi G, Mai B, Jensen PR, Fenical WF, Neuteboom ST et al: Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem (2005) 48(11):3684-3687.
124. Shibasaki M, Kanai M, Fukuda N: Total synthesis of lactacystin and salinosporamide A. Chem Asian J (2007) 2(1):20-38.
125. Ling T, Macherla VR, Manam RR, McArthur KA, Potts BC: Enantioselective total synthesis of (-)-salinosporamide A (NPI-0052). Org Lett (2007) 9(12):2289-2292.
126. Fukuda T, Sugiyama K, Arima S, Harigaya Y, Nagamitsu T, Omura S: Total synthesis of salinosporamide A. Org Lett (2008) 10(19):4239-4242.
127. Manam RR, McArthur KA, Chao TH, Weiss J, Ali JA, Palombella VJ, Groll M, Lloyd GK, Palladino MA, Neuteboom ST, Macherla VR et al: Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides. J Med Chem (2008) 51(21):6711-6724.
128. Jensen PR, Williams PG, Oh DC, Zeigler L, Fenical W: Species-specific secondary metabolite production in marine actinomycetes of the genus Salinispora. App Environ Microbiol (2007) 73(4): 1146-1152.
129. Lam KS, Tsueng G, McArthur KA, Mitchell SS, Potts BCM, Xu J: Effects of halogens on the production of salinosporamides by the obligate marine actinomycete Salinispora tropica. J Antibiot (2007) 60(1):13-19.
130. Reed KA, Manam RR, Mitchell SS, Xu J, Teisan S, Chao TH, Deyanat-Yazdi G, Neuteboom ST, Lam KS, Potts BC: Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome. J Nat Prod (2007) 70(2):269-276.
131. Tsueng G, Lam KS: Stabilization effect of resin on the production of potent proteasome inhibitor NPI-0052 during submerged fermentation of Salinispora tropica. J Antibiot (2007) 60(7):469-472.
132. Groll M, Huber R, Potts BCM: Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc (2006) 128(15):5136-5141.
133. Denora N, Potts BC, Stella VJ: A mechanistic and kinetic study of the lactone hydrolysis of salinosporamide A (NPI-0052), a novel proteasome inhibitor. J Pharm Sci (2007) 96(8):2037-2047.
134. Kurzrock R, Hamlin P, Younes A, Hong D, Gordon M, Spear MA, Palladino MA, Lloyd GK, Longenecker AM, Neuteboom STC, Cropp GF et al: Phase 1 clinical trial of a novel proteasome inhibitor (NPI-0052) in patients with lymphomas and solid tumors. Blood (2007) 110(11):Abs 4504.
135. Handelsman J, Rondon MR, Brady SF, Clardy J, Goodman RM: Molecular biological access to the chemistry of unknown soil microbes: A new frontier for natural products. Chem Biol (1998) 5(10):R245-R249.
136. Rondon MR, August PR, Bettermann AD, Brady SF, Grossman TH, Liles MR, Loiacono KA, Lynch BA, MacNeil IA, Minor C, Tiong CL et al: Cloning the soil metagenome: A strategy for accessing the genetic and functional diversity of uncultured microorganisms. Appl Environ Microbiol (2000) 66(6):2541-2547.
137. Rusch DB, Halpern AL, Sutton G, Heidelberg KB, Williamson S, Yooseph S, Wu D, Eisen JA, Hoffman JM, Remington K, Beeson K et al: The Sorcerer II global ocean sampling expedition: Northwest Atlantic through Eastern Tropical Pacific. PLoS Biology (2007) 5(3):e77.
138. Omura S, Ikeda H, Ishikawa J, Hanamoto A, Takahashi C, Shinose M, Takahashi Y, Horikawa H, Nakazawa H, Osonoe T, Kikuchi H et al: Genome sequence of an industrial microorganism Streptomyces avermitilis: Deducing the ability of producing secondary metabolites. Proc Nat Acad Sci USA (2001) 98(21):12215-12220.
139. Ikeda H, Ishikawa J, Hanamoto A, Shinose M, Kikuchi H, Shiba T, Sakaki Y, Hattori M, Omura S: Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis. Nat Biotechnol (2003) 21(5):526-531.
140. Bentley SD, Chater KF, Cerdeño-Tárraga AM, Challis GL, Thomson NR, James KD, Harris DE, Quail MA, Kieser H, Harper D, Bateman A et al: Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature (2002) 417(6885):141-147.
141. Udwary DW, Zeigler L, Asolkar RN, Singan V, Lapidus A, Fenical W, Jensen PR, Moore BS: Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. Proc Natl Acad Sci USA (2007) 104(25): 10376-10381.
142. Eustáquio AS, Pojer F, Noel JP, Moore BS: Discovery and characterization of a marine bacterial SAM-dependent chlorinase. Nat Chem Biol (2008) 4(1):69-74.
143. Eustaquio AS, Moore BS: Mutasynthesis of fluorosalinosporamide, a potent and reversible inhibitor of the proteasome. Angew Chem Int Ed (2008) 47(21):3936-3938.
144. Stierle A, Strobel G, Stierle D: Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science (1993) 260(5105):214-216.
145. Li JY, Sidhu RS, Bollon A, Strobel GA: Stimulation of taxol production in liquid cultures of Pestalotiopsis microspora. Mycol Res (1998) 102(4):461-464.
146. Puri SC, Verma V, Amna T, Qazi GN, Spiteller M: An endophytic fungus from Nothapodytes foetida that produces camptothecin. J Nat Prod (2005) 68(12):1717-1719.
147. Amna T, Puri SC, Verma V, Sharma JP, Khajuria RK, Musarrat J, Spiteller M, Qazi GN: Bioreactor studies on the endophytic fungus Entrophospora infrequens for the production of an anticancer alkaloid camptothecin. Can J Microbiol (2006) 52(3):189-196.
148. Kusari S, Zühlke S, Spiteller M: An endophytic fungus from Camptotheca acuminata that produces camptothecin and analogues. J Nat Prod (2009) 72(1):2-7.
149. Eyberger AL, Dondapati R, Porter JR: Endophyte fungal isolates from Podophyllum peltatum produce podophyllotoxin. J Nat Prod (2006) 69(8):1121-1124.
150. Puri SC, Nazir A, Chawla R, Arora R, Riyaz-Ul-Hasan S, Amna T, Ahmed B, Verma V, Singh S, Sagar R, Sharma A et al: The endophytic fungus Trametes hirsuta as a novel alternative source of podophyllotoxin and related aryl tetralin lignans. J Biotech (2006) 122(4):494-510.
151. Guo B, Li H, Zhang L: Isolation of a fungus producing vinblastine. J Yunnan Univ (1998) 20:214-215.
152. Zhang LQ, Guo B, Li H, Zeng S, Shao H, Gu S, Wei R: Preliminary study on the isolation of endophytic fungus of Catharanthus roseus and its fermentation to produce product of therapeutic value. Chinese Traditional Herb Drugs (2000) 31: 805-807.
153. Yang X, Zhang L, Guo B, Guo S: Preliminary study of a vincristine-producing endophytic fungus isolated from leaves of Catharanthus roseus. Chinese Traditional Herb Drugs (2004) 35(1):79-81.
154. Bok JW, Hoffmeister D, Maggio-Hall LA, Murillo R, Glasner JD, Keller NP: Genomic mining for Aspergillus natural products. Chem Biol (2006) 13(1):31-37.
155. Hoffmeister D, Keller NP: Natural products of filamentous fungi: Enzymes, genes and their regulation. Nat Prod Rep (2007) 24(2):393-416.
156. Brakhage AA, Schuemann J, Bergmann S, Scherlach K, Schroeckh V, Hertweck C: Activation of fungal silent gene clusters: A new avenue to drug discovery. In: Progress in Drug Research. Petersen F, Amstutz R (Eds), Birkhauser Verlag, Basel, Switzerland (2008) 66:3-12.
157. Fox EM, Howlett BJ: Secondary metabolism: Regulation and role in fungal biology. Curr Opin Microbiol (2008) 11(6):481-487.
158. Stadler M, Keller NP: Paradigm shifts in fungal secondary metabolite research. Mycol Res (2008) 112(Pt 2):127-130.
159. Lefevre F, Robe P, Jarrin C, Ginolhac A, Zago C, Auriol D, Vogel TM, Simonet P, Nalin R: Drugs from hidden bugs: Their discovery via untapped resources. Res Microbiol (2008) 159(3):153-161.
160. Lee SY, Kim HU, Park JH, Park JM, Kim TY: Metabolic engineering of microorganisms: General strategies and drug production. Drug Disc Today (2009) 14(1-2):78-88.
161. Krug D, Zurek G, Revermann O, Vos M, Velicer GJ, Müller R: Discovering the hidden secondary metabolome of Myxococcus xanthus: A study of intraspecific diversity. Appl Environ Microbiol (2008) 74(10):3058-3068.
162. Krug D, Zurek G, Schneider B, Garcia R, Müller R: Efficient mining of myxobacterial metabolite profiles enabled by liquid chromatography- electrospray ionisation-time-of-flight mass spectrometry and compound-based principal component analysis. Anal Chim Acta (2008) 624(1):97-106.
163. Meiser P, Weissman KJ, Bode HB, Krug D, Dickschat JS, Sandmann A, Muller R: DKxanthene biosynthesis - understanding the basis for diversity-oriented synthesis in myxobacterial secondary metabolism. Chem Biol (2008) 15(8):771-781.
164. Menche D: New methods for stereochemical determination of complex polyketides: Configurational assignment of novel metabolites from myxobacteria. Nat Prod Rep (2008) 25(5): 905-918.
165. Esquenazi E, Coates C, Simmons TL, Gonzalez D, Gerwick WH, Dorrestein PC: Visualizing the spatial distributon of secondary metabolites produced by marine cyanobacteria and sponges via MALDI-TOF imaging. Mol Biosystems (2008) 4(6):562-570.
166. Simmons TL, Coates RC, Clark BR, Engene N, Gonzalez D, Esquenazi E, Dorrestein PC, Gerwick WH: Biosynthetic origin of natural products isolated from marine microorganisminvertebrate assemblages. Proc Natl Acad Sci USA (2008) 105(12):4587-4594.
167. Piel J: Combinatorial biosynthesis in symbiotic bacteria. Nat Chem Biol (2006) 2(12):661-662.
168. Piel J: Bacterial symbionts: Prospects for the sustainable production of invertebrate-derived pharmaceuticals. Curr Med Chem (2006) 13(1):39-50.
169. Fieseler L, Hentschel U, Grozdanov L, Schirmer A, Wen G, Platzer M, Hrvatin S, Butzke D, Zimmermann K, Piel J: Widespread occurrence and genomic context of unusually small polyketide synthase genes in microbial consortia associated with marine sponges. Appl Environ Microbiol (2007) 73(7):2144-2155.
170. Partida-Martinez LP, Hertweck C: A gene cluster encoding rhizoxin biosynthesis in "Burkholderia rhizoxina", the bacterial endosymbiont of the fungus Rhizopus microsporus. ChemBioChem (2007) 8(1):41-45.
171. Ziemert N, Ishida K, Quillardet P, Bouchier C, Hertweck C, de Marsac NT, Dittmann E: Microcyclamide biosynthesis in two strains of Microcystis aeruginosa: From structure to genes and vice versa. Appl Environ Microbiol (2008) 74(6):1791-1797.
172. Gunatilaka AA: Natural products from plant-associated microorganisms: Distribution, structural diversity, bioactivity, and implications of their occurrence. J Nat Prod (2006) 69(3): 509-526.
173. University of Wisconsin-Milwaukee (Cheng YQ): Sequences and methods for biosynthesis of FK-228 and analogs thereof - Useful as histone deacetylase inhibitors, eg for treating cancer. WO-2008098199 (2008).
174. University of Maryland/University of Mississippi (Hill RT, Hamann MT, Enticknap J, Rao KV): Isolated Vibrio bacterium, which produces a kahalalide - useful for treating AIDS, opportunistic infections and cancer. WO-2005042720 (2005).